Seeking Alpha

US Supreme Court mum on Teva vs Sandoz case

  • No word on whether the Supreme Court will hear Teva Pharma's (TEVA -1.3%) patent case regarding the generic encroachment on its multiple sclerosis drug.
  • Predictably, Teva is keen to have its case reviewed in light of the US Court of Appeals verdict in July invaliding several of Copaxone's patents.
  • The case is, again, missing from the list of actionable cases published by the court today.
  • If it declines to pick up the matter generics could debut as early as May.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs